Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2723-2728

  Saikawa, Yoshiro ^a   Sugiura, Tsudoi ^a   Toriumi, Fumiki ^a   Kubota, Tetsuro ^a   Suganuma, Kazuhiro ^a   Isshiki, Soichiro ^b   Otani, Yoshihide ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Cisplatin; Colon cancer cell; Cyclooxygenase 2; MDR 1; MRP 1

Indexed keywords

ABC TRANSPORTER; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TILMACOXIB;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FAMILY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OXAZOLES; P-GLYCOPROTEIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER;

EID: 6444222237     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K and Gazdar AF: MDR1 gene expression in lung cancer. J Natl Cancer Inst (Bethesda) 81: 1144-1150, 1989.
2. Hipfner DR, Gauldie SD, Deeley RGD and Cole SPC: Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54: 5788-5792, 1994.
3. Klein I, Sarkadi B and Varadi A: An inventory of the human ABC proteins. Biochim Biophys Acta 1461: 237-262, 1999
4. Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (p-glycoprptein) by cyclooxygenase-2. J Biol Chem 11: 38915-38920, 2002.
5. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
6. Simon LS: Biologic effects of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 9: 178-182, 1997.
7. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2, a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24(2): 96-102, 2003.
8. Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. Cancer Res 53: 1322-1327, 1993.
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in woman. N Engl J Med 333: 609-614, 1995.
10. Campling BG, Young LC, Baer K, Lam YM, Deeley RG, Cole SPC and Gerlach JH: Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3: 115-122, 1997.
11. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SPC, Deeley RG and Gerlach JH: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5: 673-680, 1999.
12. Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804, 2001
13. Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M and Sugimachi K: Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 68: 372-377, 1996.
14. Chan HLS, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SPC, Deeley RG, Ling V and Gallie BL: Multidrug-resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57: 2325-2330, 1997.
15. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zochbauer S, Brunner R, Lechner K and Pirker R: MRP expression in acute myeloid leukemia. Tn: Drug Resistance in Leukemia and Lymphoma, Kaspers GJL, Pieters R and Veerman AJP eds, Vol. 3: 141-150, Kluwer Academic/Plenum Publishers New York 1999.
16. Matsushita M, Masaki M, Yagi Y, Tanaka T and Wakitani K: Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats. Inflamm Res 46: 461-466, 1997.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Fukushima M, Okabe H, Takechi T, Ichikawa W and Hirayama R: Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 187: 103-10, 2002.
19. Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G and Verweij J: Phase I and pharmacologie study of docetael and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071-1079, 1997.
20. Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS and Kim HK: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 7: 114-119, 2002.
21. Glisson BS, Murphy BA, Frenette G, Frenette G, Khuri FR and Forastiere AA: Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 15: 1593-1500, 2002.
22. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
23. Shen DW, Pastan I and Gottesman MM: Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58: 268-275, 1998.
24. Adachi S, Obaya AJ, Han Z, Ramos-Desimone N, Wyche JH and Sedivy JM: c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol 21: 4929-4937, 2001.
25. Ishikawa T, Bao TT, Yamane Y, Akimaru K, Frindrich K, Wright CD and Kuo MT: Coordinated induction of MRP/GS-X pump and -glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981-14988, 1996.
26. Rong R, He Q, Liu Y, Sheikh MS and Huang Y: TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-B signaling pathway. Oncogene 21: 1062-1070, 2002.
27. Sharp SY, Smith V, Hobbs S and Kelland LR: Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell line. Br J Cancer 78: 175-180, 1998.
28. 14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183: 108-116, 2000.
29. Wakitani K, Nanayama T, Masaki M and Matsushita M: Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. Jpn J Pharmacol 78(3): 365-371, 1998.
30. Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277(41): 38915-38920, 2002.
31. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21(3C): 2141-2147, 2001.
32. Touhey S, O'Connor R, Plunkett S, Maguire A and Clynes M: Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. Identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer 38(12): 1661-1670, 2002.
33. Dimberg J, Hugander A, Sirsjo A and Soderkvist P: Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 21: 911-915, 2001.
34. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
35. Sugiura T, Saikawa Y, Kubota T, Suganuma K, Otani Y, Watanabe M, Kumai K and Kitajima M: Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 17(3): 229-233, 2003.
36. Wei M, Morimura K, Wanibuchi H, Shen J, Doi K, Mitsuhashi M, Moku M, Salim EI and Fukushima S: Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Cancer Lett 202(7): 11-16, 2003.
37. Uefuji K, Ichikura T, Shinomiya N and Mochizuki H: Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 20(6B): 4279-4284, 2000.
38. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD and DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259, 1997.